NRC
ALIM

North Run Capital’s Alimera Sciences ALIM Stock Holding History

North Run Capital’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-115,333
Closed -$1.87M – 22
2016
Q4 		$1.87M Sell
115,333
-117,807
-51% -$2.16M 0.57% 17
2016
Q3 		$5.21M Sell
233,140
-193
-0.1% -$4.44K 0.82% 24
2016
Q2 		$4.3M Hold
233,333
– – 0.71% 24
2016
Q1 		$6.13M Hold
233,333
– – 0.84% 22
2015
Q4 		$8.47M Hold
233,333
– – 1% 23
2015
Q3 		$7.74M Buy
233,333
+3,449
+2% +$194K 0.76% 28
2015
Q2 		$15.9M Buy
229,884
+31,551
+16% +$2.18M 1.56% 19
2015
Q1 		$14.9M Buy
198,333
+56,618
+40% +$4.45M 1.63% 18
2014
Q4 		$11.8M Hold
141,715
– – 1.05% 21
2014
Q3 		$11.5M Buy
141,715
+11,715
+9% +$1M 1.04% 25
2014
Q2 		$11.7M Buy
130,000
+22,295
+21% +$1.98M 1.13% 20
2014
Q1 		$12.7M Sell
107,705
-1,186
-1% -$115K 1.3% 21
2013
Q4 		$7.69M Sell
108,891
-17,776
-14% -$724K 0.97% 22
2013
Q3 		$7.14M Hold
126,667
– – 0.93% 21
2013
Q2 		$9.27M Buy
+126,667
New +$7.31M 1.08% 23

Other funds holding ALIM

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

North Run Capital's ALIM Position: Q1 2017 in Review

North Run Capital sold out of Alimera Sciences (ALIM) in Q1 2017, closing a stake of 115,333 shares — an estimated $1.87M sold.

North Run Capital first reported a position in ALIM in Q2 2013 and held it in 15 quarters. The position peaked at $15.9M in Q2 2015. 39 funds tracked by Wall St. Rank hold ALIM as of Q1 2017.

  • North Run Capital reported no remaining Alimera Sciences position as of Q1 2017 after selling out during the quarter.
  • North Run Capital sold 115,333 Alimera Sciences shares in Q1 2017, an estimated $1.87M.
  • North Run Capital first reported a position in Alimera Sciences in Q2 2013 and held it in 15 quarters.
  • North Run Capital's Alimera Sciences position peaked at $15.9M in Q2 2015.
  • 39 funds tracked by Wall St. Rank held Alimera Sciences as of Q1 2017.

Based on North Run Capital's 13F filing for Q1 2017, filed 12 May 2017.